The Centers for Medicare & Medicaid Services Aug. 15 released a state funding notice for the Cell and Gene Therapy Access Model. The CGT Access Model will test whether a CMS-led approach to developing and administering outcomes-based agreements for cell and gene therapies improves Medicaid beneficiaries’ health outcomes, broadens access to innovative treatment and reduces health care expenditures. It will initially focus on gene therapies for sickle cell disease. The notice includes an opportunity for applicants to apply for cooperative agreement funding to support participation in the CGT Access Model. Applicants must apply for participation in the model through a state applications request and apply for funding through the state funding notice, both of which are due Feb. 28, 2025. The award date is anticipated for July 1, 2025. 

Related News Articles

Headline
The AHA June 10 released a new video in its series, “Medicaid: Real Lives, Real Care,” that features Missouri Hospital Association President and CEO Jon…
Headline
The White House June 6 issued a memorandum directing the Secretary of the Department of Health and Human Services “to take appropriate action to eliminate…
Headline
A Congressional Budget Office report released June 4 found that enactment of the fiscal year 2025 budget reconciliation bill, the One Big Beautiful Bill Act (H…
Headline
The AHA June 3 launched the first in a new video series, “Medicaid: Real Lives, Real Care,” highlighting the importance of Medicaid and why proposed cuts…
Headline
The Wall Street Journal today published online a letter to the editor from AHA President and CEO Rick Pollack responding to a recent editorial, “The…
Perspective
Public
After approval in the House last week by a one vote margin, the One Big Beautiful Bill Act — a sweeping package that would enact many of President Trump’s…